What is the investment case, and what must be true for it to hold?
SciBase Holding can sustain its sales growth because third-quarter sales rose 41%, contingent on securing further long-term financing; the board's stated funding shortfall is the chief threat to that condition. The quarterly increase was led by demand in the United States and by recurring electrode sales.
The board determined that available capital remained insufficient to fund operations over the coming 12 months, even after the most recent rights issue.
2Risk Factors
Which risks could break the thesis, and what would warn of them?
Access to financing is the most immediate risk to SciBase Holding's continuity, because the board concluded that available capital would not cover operations over the coming 12 months even after the company's latest rights issue.
SciBase Holding's cash flow from current operations was negative in the amount of TSEK 81,667.
3Product Overview
What does the product do for its buyer, and how is it delivered?
Nevisense's skin-assessment workflow is measurement-led, using EIS to assess the skin's bioelectrical signature at multiple frequencies and depths.
Nevisense is a compact, portable device serving clinical practice and research environments.
SciBase Holding
SciBase Holding develops point-of-care skin-health platforms, including Nevisense and Nevisense Go, which detect skin cancer.